These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 6244995)

  • 21. Studies on neurovirulence in poliovirus-sensitive transgenic mice and cynomolgus monkeys for the different temperature-sensitive viruses derived from the Sabin type 3 virus.
    Abe S; Ota Y; Doi Y; Nomoto A; Nomura T; Chumakov KM; Hashizume S
    Virology; 1995 Jun; 210(1):160-6. PubMed ID: 7793068
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proposals on the control of VERO cells used to prepare inactivated poliomyelitis vaccine.
    Ménetrat JL; Chaniot S; Lefrançois S; Canale A; Chippaux A
    Dev Biol Stand; 1981; 47():163-7. PubMed ID: 6785125
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tissue culture of viruses (author's transl).
    Can J Med Technol; 1974 Jun; 36(3):231 passim. PubMed ID: 4368290
    [No Abstract]   [Full Text] [Related]  

  • 24. Susceptibility of continuous lines of monkey kidney cells to influenza and parainfluenza viruses in the presence of trypsin.
    Orstavik I
    Acta Pathol Microbiol Scand B; 1981 Jun; 89(3):179-83. PubMed ID: 6274142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Studies on characteristics of poliovirus. II. Plaque-forming capacity of attenuated poliovirus strains in human and monkey kidney cell cultures.
    Böttiger M
    Arch Gesamte Virusforsch; 1966; 18(2):127-34. PubMed ID: 4293024
    [No Abstract]   [Full Text] [Related]  

  • 26. Some aspects of the monkey neurovirulence test used for the assessment of oral poliovirus vaccines.
    Furesz J; Contreras G
    Dev Biol Stand; 1993; 78():61-70. PubMed ID: 8388832
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Replication of poliovirus (LSc 2 ab) in perfused cultures of MRC-5 diploid cells.
    Mann GF; de Mucha J
    Dev Biol Stand; 1976 Dec 13-15; 37():255-8. PubMed ID: 201522
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of proflavine-sensitized poliovirus strains for determination of the range of susceptible animals.
    Koroleva GA; Lashkevich VA; Voroshilova MK
    Acta Virol; 1973 Jul; 17(4):310-8. PubMed ID: 4148211
    [No Abstract]   [Full Text] [Related]  

  • 29. Anomalous observations on IPV and OPV vaccination.
    John TJ
    Dev Biol (Basel); 2001; 105():197-208. PubMed ID: 11763328
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An enzyme-linked immunosorbent assay, ELISA, for SV40 antigen detection.
    Edevåg G; Grandien M; Mares I
    J Virol Methods; 1985 Aug; 11(4):347-55. PubMed ID: 2997255
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The monitoring of antigen levels during inactivated poliovirus vaccine production: evaluation of filtration techniques.
    Moynihan M; Petersen I
    Dev Biol Stand; 1981; 50():243-8. PubMed ID: 6804290
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Studies on the initial phases of poliovirus reproduction cycle. II. Comparative studies on HeLa and permanent monkey kidney cells.
    György E; Lomniczi B; Koch A
    Acta Microbiol Acad Sci Hung; 1966; 13(3):235-41. PubMed ID: 4289411
    [No Abstract]   [Full Text] [Related]  

  • 33. Comparative pre-clinical and clinical experience with oral polio vaccine produced on MRC-5 cells or on primary monkey kidney cells.
    Prikazsky V; Leroux-Roels G; Van Damme P; Safary A; Colau B; Duchene M
    Vaccine; 2005 Jul; 23(33):4219-27. PubMed ID: 15936120
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thousand litre scale microcarrier culture of Vero cells for killed polio virus vaccine. Promising results.
    Montagnon B; Vincent-Falquet JC; Fanget B
    Dev Biol Stand; 1983; 55():37-42. PubMed ID: 6677539
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative study of poliovirus excretion after vaccination of infants with two oral polio vaccines prepared on Vero cells or on primary monkey kidney cells.
    Mallet L; Pelloquin F; Brigaud M; Caudrelier P; Bandet R; Xueref C; Fuchs F; Gibelin N; Goldman C; Moulin JC; de Fraipont F; Montagnon B; Peyron L; Aymard M
    J Med Virol; 1997 May; 52(1):50-60. PubMed ID: 9131458
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trypsin in poliovaccine manufacture.
    Hayflick L
    Lancet; 1994 Mar; 343(8897):611. PubMed ID: 7906374
    [No Abstract]   [Full Text] [Related]  

  • 37. Immunogenicity of trypsin treated type 2 and type 3 poliovirus in rats.
    Kersten GF; Lantinga M; Hazendonk T; Beuvery EC
    Biologicals; 1995 Jun; 23(2):179-83. PubMed ID: 7546661
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Counterimmunoelectrophoresis of SV40 and its application in quality control and production of poliovaccine].
    Ye M
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1988 Feb; 10(1):64-7. PubMed ID: 2838191
    [No Abstract]   [Full Text] [Related]  

  • 39. Mutations in Sabin 2 strain of poliovirus and stability of attenuation phenotype.
    Rezapkin GV; Fan L; Asher DM; Fibi MR; Dragunsky EM; Chumakov KM
    Virology; 1999 May; 258(1):152-60. PubMed ID: 10329577
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Replication and plaque formation of parainfluenza viruses in an established line of monkey kidney cells.
    Nerome K; Ishida M
    Acta Virol; 1982 May; 26(3):183-5. PubMed ID: 6127019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.